Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Jayna J Mistry; Charlotte Hellmich; Amelia Lambert; Jamie A Moore; Aisha Jibril; Angela Collins; Kristian M Bowles; Stuart A Rushworth

doi:10.1186/s40364-021-00291-y

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia

Biomark Res. 2021 May 13;9(1):35. doi: 10.1186/s40364-021-00291-y.

Authors

Jayna J Mistry^{1

2}, Charlotte Hellmich^{1

3}, Amelia Lambert¹, Jamie A Moore¹, Aisha Jibril¹, Angela Collins³, Kristian M Bowles^{4

5

6}, Stuart A Rushworth^{7

8}

Affiliations

¹ Norwich Medical School, University of East Anglia, Norwich Research Park, NR4 7UQ, Norwich, UK.
² Earlham Institute, Norwich Research Park, NR4 7UH, Norwich, UK.
³ Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Colney Lane, NR4 7UY, Norwich, UK.
⁴ Norwich Medical School, University of East Anglia, Norwich Research Park, NR4 7UQ, Norwich, UK. k.bowles@uea.ac.uk.
⁵ Department of Haematology, Norfolk and Norwich University Hospitals NHS Trust, Colney Lane, NR4 7UY, Norwich, UK. k.bowles@uea.ac.uk.
⁶ Department of Molecular Haematology, Norwich Medical School, Norwich Research Park, NR4 7UQ, Norwich, UK. k.bowles@uea.ac.uk.
⁷ Norwich Medical School, University of East Anglia, Norwich Research Park, NR4 7UQ, Norwich, UK. s.rushworth@uea.ac.uk.
⁸ Department of Molecular Haematology, Norwich Medical School, Norwich Research Park, NR4 7UQ, Norwich, UK. s.rushworth@uea.ac.uk.

Abstract

Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combination resulted in a slower tumor progression and a reduced leukemia growth both in vitro and in vivo. These data provide evidence for clinical evaluation of Venetoclax and Daratumumab combination in the treatment of AML.

Publication types

Letter

Abstract

Publication types

Grants and funding